Amgen Inc. (TSX:AMGN)

Market Cap	269.68B +27.3%
Revenue (ttm)	50.39B +10.0%
Net Income	10.57B +88.5%
EPS	19.51 +88.2%
Shares Out	n/a
PE Ratio	25.51
Forward PE	16.32
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,487
Average Volume	2,014
Open	25.60
Previous Close	25.80
Day's Range	25.60 - 25.61
52-Week Range	24.00 - 26.12
Beta	n/a
RSI	54.14
Earnings Date	Feb 3, 2026

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1980
• Employees: 28,000
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: AMGN

Financial Performance

In 2025, Amgen's revenue was $36.75 billion, an increase of 9.95% compared to the previous year's $33.42 billion. Earnings were $7.71 billion, an increase of 88.53%.

Financial numbers in USD